CJC-1295 No DAC & Ipamorelin Pharmacokinetics Explained

CJC-1295 No DAC & Ipamorelin Pharmacokinetics Explained

A 2018 study published in The Journal of Clinical Endocrinology & Metabolism found that CJC-1295 without DAC (drug affinity complex) has a plasma half-life of approximately 30 minutes. Meaning the compound clears the bloodstream fast enough that multiple daily administrations are required to maintain therapeutic plasma levels. Ipamorelin, meanwhile, persists for roughly 2 hours post-injection before degradation. That pharmacokinetic gap matters more than most researchers realize. It dictates dosing timing, administration frequency, and whether peptide stacking produces synergy or saturation.

We've guided hundreds of research teams through peptide protocols. The gap between executing a well-timed dosing regimen and undermining data validity comes down to three pharmacokinetic details most guides never mention: elimination half-life variance, peak concentration timing, and receptor occupancy windows.

What Are the Pharmacokinetics of CJC-1295 No DAC and Ipamorelin?

CJC-1295 No DAC (also called Modified GRF 1-29) has a plasma elimination half-life of 30 minutes and reaches peak serum concentration approximately 15–30 minutes post-subcutaneous injection. Ipamorelin has a half-life of approximately 2 hours, with peak concentration occurring 30–45 minutes after administration. These pharmacokinetic profiles require dosing 2–3 times daily to maintain consistent growth hormone-releasing hormone (GHRH) and growth hormone secretagogue (GHS) receptor activation throughout a 24-hour cycle.

Most peptide protocols get this wrong. The basic answer. 'inject before bed'. Misses the mechanism entirely. CJC-1295 No DAC stimulates growth hormone (GH) release through GHRH receptor binding at the pituitary level, but the compound clears so rapidly that a single bedtime injection produces only one pulsatile GH spike before the peptide is metabolized. Ipamorelin, a selective ghrelin mimetic, acts on ghrelin receptors to amplify GH secretion without elevating prolactin or cortisol. Its longer half-life allows for slightly more sustained receptor activation, but it still degrades within 4–6 hours of administration. This article covers the precise half-life and clearance mechanisms for both peptides, how absorption and distribution kinetics differ between them, and what dosing timing errors negate their synergistic potential entirely.

Absorption and Distribution Kinetics for CJC-1295 No DAC

CJC-1295 No DAC is administered via subcutaneous injection, where it enters systemic circulation through capillary absorption at the injection site. Bioavailability via subcutaneous route is estimated at 85–95%. Higher than oral peptides (which undergo proteolytic degradation in the gastric environment) but slightly lower than intravenous administration due to localized enzymatic breakdown at the injection depot. Peak plasma concentration occurs 15–30 minutes post-injection, with GH pulse initiation beginning within 10–15 minutes as the peptide crosses the blood-brain barrier and binds to GHRH receptors on somatotroph cells in the anterior pituitary.

Volume of distribution (Vd) for CJC-1295 No DAC is approximately 0.3–0.5 L/kg, indicating limited tissue penetration beyond the vascular compartment. The peptide remains primarily in plasma and extracellular fluid rather than diffusing into adipose or muscle tissue. This confined distribution contributes to the rapid clearance rate: the peptide is enzymatically degraded by dipeptidyl peptidase-IV (DPP-IV) and neutral endopeptidases in plasma within 30 minutes, producing metabolites that are renally excreted. The short half-life is a deliberate feature of the 'No DAC' formulation. Removal of the drug affinity complex eliminates albumin binding, preventing the multi-day half-life extension seen in CJC-1295 with DAC but also requiring more frequent dosing to sustain receptor activation.

Our team has worked with research protocols across hundreds of peptide studies. The reconstitution step is where most pharmacokinetic integrity is lost. Lyophilized CJC-1295 No DAC must be reconstituted with bacteriostatic water at controlled pH (6.0–7.5) to prevent peptide bond hydrolysis, and the reconstituted solution must be refrigerated at 2–8°C to slow enzymatic degradation before use.

Ipamorelin Metabolism and Elimination Pathways

Ipamorelin is metabolized primarily through enzymatic degradation by peptidases in plasma and hepatic tissue, with an elimination half-life of approximately 2 hours in human subjects. Peak serum concentration occurs 30–45 minutes post-subcutaneous administration, followed by a gradual decline as the peptide undergoes proteolysis. Unlike non-selective GH secretagogues (GHRP-2, GHRP-6), ipamorelin does not significantly activate prolactin or cortisol release pathways, limiting off-target receptor binding and secondary metabolic effects.

Clearance occurs through two primary routes: enzymatic degradation in plasma by endopeptidases (similar to CJC-1295 No DAC) and hepatic metabolism via cytochrome P450-independent proteolytic pathways. Renal excretion accounts for 60–70% of metabolite clearance, with biliary excretion responsible for the remainder. The compound does not undergo significant enterohepatic recirculation, meaning once metabolized, ipamorelin fragments are excreted rather than reabsorbed. Contributing to the relatively predictable pharmacokinetic profile across repeat dosing.

The 2-hour half-life creates a dosing timing constraint most protocols ignore: ipamorelin administered more than 4 hours after CJC-1295 No DAC produces minimal synergistic GH release because the GHRH receptor activation window has already closed. Simultaneous or staggered administration within 30–60 minutes produces the most reliable amplification. Ipamorelin's ghrelin receptor activation potentiates the GH pulse initiated by CJC-1295 No DAC, but only if both peptides reach peak concentration while pituitary somatotrophs remain responsive.

Dosing Timing and Receptor Occupancy Windows

The pharmacokinetic profiles of CJC-1295 No DAC and ipamorelin dictate specific timing windows for synergistic GH release. GHRH receptors on anterior pituitary somatotrophs respond to CJC-1295 No DAC binding by initiating intracellular signaling cascades (cAMP elevation, protein kinase A activation) that trigger GH vesicle exocytosis. This process takes 10–15 minutes from peptide administration to measurable serum GH elevation. Ipamorelin, acting on ghrelin receptors, amplifies this response by inhibiting somatostatin release (the endogenous GH inhibitor) and directly stimulating somatotroph secretory activity.

For maximal synergy, both peptides should reach peak plasma concentration within overlapping timeframes. Typically achieved by administering them simultaneously or with ipamorelin injected 10–20 minutes after CJC-1295 No DAC. Delays beyond 60 minutes reduce amplification potential because CJC-1295 No DAC has already been cleared from circulation by the time ipamorelin reaches peak receptor occupancy. Research teams at the University of Virginia's Department of Endocrinology demonstrated that co-administration produced 2.5× greater GH pulse amplitude compared to staggered dosing at 90-minute intervals, underscoring the importance of pharmacokinetic alignment.

Dosing frequency must account for both peptides' elimination half-lives. CJC-1295 No DAC requires administration 2–3 times daily to maintain consistent GHRH receptor activation. Single daily dosing produces only one transient GH pulse followed by 20+ hours of subtherapeutic plasma levels. Ipamorelin's longer half-life allows for slightly less frequent dosing (twice daily), but most research protocols use matched timing (e.g., morning and pre-sleep administration) to simplify compliance and ensure both peptides are active simultaneously.

CJC-1295 No DAC & Ipamorelin: Pharmacokinetic Comparison

Elimination Half-Life

~30 minutes

~2 hours

CJC requires 2–3x daily dosing; ipamorelin can extend to 2x daily

Peak Plasma Concentration

15–30 minutes post-injection

30–45 minutes post-injection

Co-administer or stagger by ≤20 minutes for synergy

Receptor Target

GHRH receptors (anterior pituitary)

Ghrelin receptors (ghrelin mimetic)

Complementary pathways. Synergistic GH release when timed correctly

Volume of Distribution

0.3–0.5 L/kg

~0.6 L/kg

Both remain primarily in plasma/extracellular fluid

Primary Metabolism Route

DPP-IV enzymatic degradation

Plasma peptidases + hepatic proteolysis

Both clear rapidly. No accumulation with standard dosing

Off-Target Effects

Minimal

No prolactin/cortisol elevation (unlike GHRP-2/6)

Ipamorelin safer for long-term protocols without hormonal disruption

Key Takeaways

CJC-1295 No DAC has a plasma half-life of approximately 30 minutes, requiring 2–3 daily administrations to maintain therapeutic GHRH receptor activation throughout a 24-hour cycle.

Ipamorelin persists for roughly 2 hours post-injection, with peak concentration occurring 30–45 minutes after subcutaneous administration. Longer than CJC-1295 No DAC but still requiring twice-daily dosing for sustained effect.

Co-administration or staggered dosing within 30–60 minutes produces 2.5× greater GH pulse amplitude compared to injections separated by 90+ minutes, as demonstrated in University of Virginia endocrinology research.

Both peptides undergo enzymatic degradation by plasma peptidases (DPP-IV for CJC-1295 No DAC, general endopeptidases for ipamorelin) with renal excretion of metabolites. Neither accumulates with standard dosing schedules.

Volume of distribution for both peptides is confined to plasma and extracellular fluid (0.3–0.6 L/kg), meaning they do not penetrate adipose or muscle tissue significantly. Pharmacokinetic action is limited to systemic circulation.

Ipamorelin selectively activates ghrelin receptors without elevating prolactin or cortisol, making it safer than non-selective secretagogues like GHRP-2 or GHRP-6 for long-term research protocols.

What If: CJC-1295 No DAC & Ipamorelin Scenarios

What If I Dose CJC-1295 No DAC Only Once Daily?

You'll produce one transient GH pulse followed by 20+ hours of subtherapeutic plasma levels. CJC-1295 No DAC's 30-minute half-life means the peptide is 99% cleared within 2.5 hours post-injection. Any receptor activation beyond that window is negligible. Research protocols designed around single daily dosing fail to maintain consistent GHRH receptor occupancy, producing sporadic GH release patterns rather than the sustained pulsatile secretion that characterizes physiological GH dynamics.

What If I Inject Ipamorelin 3 Hours After CJC-1295 No DAC?

Synergistic amplification is lost. By the time ipamorelin reaches peak plasma concentration (30–45 minutes post-injection, or 3.5–3.75 hours after the initial CJC dose), CJC-1295 No DAC has been fully metabolized and cleared from circulation. The GHRH receptor activation window has closed, leaving ipamorelin to stimulate GH release independently through ghrelin receptor pathways. Effective, but producing lower peak GH concentrations than simultaneous or near-simultaneous administration.

What If the Reconstituted Peptide Is Stored at Room Temperature?

Enzymatic degradation accelerates significantly above 8°C. Both CJC-1295 No DAC and ipamorelin are susceptible to peptide bond hydrolysis and oxidative degradation when stored improperly. A reconstituted vial left at room temperature (20–25°C) for 48 hours can lose 40–60% potency compared to refrigerated storage at 2–8°C. Lyophilized powder is more stable (store at −20°C before reconstitution), but once mixed with bacteriostatic water, the clock starts. Refrigerate immediately and use within 28 days to maintain full pharmacokinetic integrity.

The Clinical Truth About CJC-1295 No DAC & Ipamorelin Pharmacokinetics

Here's the honest answer: most peptide stacking protocols fail at the timing stage, not the dosing stage. Researchers assume that injecting both peptides 'sometime during the day' is sufficient. It's not. CJC-1295 No DAC's 30-minute half-life creates a narrow receptor activation window, and ipamorelin's 2-hour persistence doesn't compensate for poor timing. If the peptides don't reach peak plasma concentration within overlapping timeframes, the synergistic GH amplification documented in clinical trials vanishes. The pharmacokinetic data is clear: co-administration or staggered dosing within 30–60 minutes produces measurably higher GH pulse amplitude than random timing. And that difference compounds across weeks of research protocols, affecting data validity at every timepoint.

Peptide stability matters just as much as timing. We've seen countless research batches compromised by improper storage. Reconstituted CJC-1295 No DAC left in a lab drawer at ambient temperature, ipamorelin stored in a standard refrigerator alongside food items where temperature fluctuates 5–10°C every time the door opens. These aren't minor lapses. They're pharmacokinetic integrity failures that turn precisely sequenced peptides into degraded fragments with unpredictable bioavailability. If your protocol demands reproducible results, peptide handling must be as tightly controlled as dosing timing. Our team's experience across hundreds of research projects confirms this pattern every time: protocols with rigorous storage and timing controls produce clean, reproducible GH release curves; protocols with lax handling produce noisy data, failed replication attempts, and ultimately, wasted time.

CJC-1295 No DAC and ipamorelin pharmacokinetics aren't theoretical. They're the mechanical constraints that determine whether a research protocol succeeds or fails. Understanding half-life, peak concentration timing, and receptor occupancy windows isn't academic; it's the baseline requirement for valid peptide research. The mechanism works when the timing aligns. When it doesn't, even perfectly dosed peptides produce suboptimal results.

Researchers designing peptide protocols can explore verified, research-grade peptides at Real Peptides, where every batch is synthesized under strict amino-acid sequencing standards to guarantee purity and consistency across studies. For teams investigating growth hormone modulation pathways, the Body Recomp Bundle includes peptides designed for research into metabolic and anabolic signaling. Formulated with the same precision that makes CJC-1295 No DAC and ipamorelin pharmacokinetic profiles reproducible across independent labs.

Frequently Asked Questions

CJC-1295 No DAC has an elimination half-life of approximately 30 minutes, meaning plasma concentration drops to 50% of peak levels within 30 minutes post-injection and clears to below 1% within 2.5 hours. The peptide reaches peak plasma concentration 15–30 minutes after subcutaneous administration, initiating growth hormone release during that window. Because clearance is so rapid, multiple daily administrations (2–3 times) are required to maintain consistent GHRH receptor activation throughout a 24-hour research protocol.

CJC-1295 No DAC has a half-life of approximately 30 minutes, while ipamorelin persists for roughly 2 hours — a 4-fold difference in plasma elimination time. This pharmacokinetic gap means CJC-1295 No DAC clears the bloodstream significantly faster than ipamorelin, requiring more frequent dosing to maintain therapeutic levels. The difference in clearance rates also dictates optimal dosing timing: co-administration or staggered injection within 30–60 minutes ensures both peptides reach peak concentration during overlapping receptor activation windows for maximal synergistic GH release.

Yes, but timing separation reduces synergistic amplification. Research from the University of Virginia demonstrated that co-administration produces 2.5× greater GH pulse amplitude compared to staggered dosing at 90-minute intervals. For maximal synergy, both peptides should reach peak plasma concentration within overlapping timeframes — typically achieved by injecting them simultaneously or with ipamorelin administered 10–20 minutes after CJC-1295 No DAC. Delays beyond 60 minutes allow CJC-1295 No DAC to clear before ipamorelin peaks, eliminating the receptor-level amplification that makes combination protocols effective.

CJC-1295 No DAC requires 2–3 administrations per day to maintain consistent GHRH receptor activation throughout a 24-hour cycle. The 30-minute half-life means a single injection produces only one transient GH pulse followed by 20+ hours of subtherapeutic plasma levels — insufficient for protocols designed around sustained pulsatile GH secretion. Most research teams use twice-daily dosing (morning and pre-sleep) or three-times-daily dosing (morning, mid-afternoon, pre-sleep) to replicate physiological GH release patterns more closely.

Both peptides undergo enzymatic degradation in plasma — CJC-1295 No DAC is cleaved by dipeptidyl peptidase-IV (DPP-IV), while ipamorelin is broken down by general endopeptidases and hepatic proteolytic pathways. The resulting peptide fragments are metabolized into smaller amino acid components and excreted primarily through the kidneys (60–70% renal clearance) with some biliary excretion. Neither peptide undergoes significant enterohepatic recirculation, meaning once metabolized, the fragments are eliminated rather than reabsorbed — contributing to the predictable pharmacokinetic profiles and minimal accumulation risk with standard dosing schedules.

No, ipamorelin is highly selective for ghrelin receptors and does not significantly elevate cortisol or prolactin — a key pharmacological distinction from non-selective secretagogues like GHRP-2 or GHRP-6. Clinical studies confirm that ipamorelin stimulates GH release without triggering off-target hormonal disruption, making it safer for long-term research protocols where sustained cortisol or prolactin elevation would confound metabolic or endocrine endpoints. This selectivity is a direct result of ipamorelin’s molecular structure, which binds preferentially to GHS-R1a receptors without activating adjacent signaling pathways.

Reconstitution with bacteriostatic water at controlled pH (6.0–7.5) is critical to maintaining peptide bond integrity — acidic or alkaline conditions accelerate hydrolysis, degrading the peptide before administration. Once reconstituted, CJC-1295 No DAC must be refrigerated at 2–8°C to slow enzymatic degradation; storage at room temperature (20–25°C) for 48 hours can reduce potency by 40–60%. The reconstituted solution should be used within 28 days to ensure pharmacokinetic reliability — beyond that window, peptide fragmentation increases unpredictably, compromising bioavailability and reproducibility across repeat dosing.

Ipamorelin reaches peak plasma concentration approximately 30–45 minutes after subcutaneous administration, with measurable GH release initiation beginning within 20–30 minutes as the peptide binds to ghrelin receptors on pituitary somatotrophs. This timing is slightly delayed compared to CJC-1295 No DAC (which peaks at 15–30 minutes), making staggered dosing within 10–20 minutes optimal for overlapping receptor activation windows. Absorption kinetics can vary slightly based on injection site vascularity and individual metabolic factors, but the 30–45 minute peak window is consistent across research subjects.

Volume of distribution (Vd) indicates how extensively a compound penetrates tissues beyond the bloodstream. Both CJC-1295 No DAC (Vd 0.3–0.5 L/kg) and ipamorelin (Vd ~0.6 L/kg) have relatively low distribution volumes, meaning they remain primarily in plasma and extracellular fluid rather than diffusing into adipose or muscle tissue. This confined distribution contributes to rapid clearance rates — the peptides are accessible to plasma peptidases for enzymatic degradation, accelerating elimination. It also means pharmacokinetic action is limited to systemic circulation, with minimal tissue depot storage that could prolong half-life beyond the documented 30 minutes (CJC) and 2 hours (ipamorelin).

No credible pharmacokinetic data supports mixing peptides in the same vial after reconstitution — doing so introduces unpredictable degradation kinetics and potential peptide-peptide interactions that compromise stability. Both CJC-1295 No DAC and ipamorelin should be reconstituted separately, stored in individual vials at 2–8°C, and drawn into separate syringes for administration. Co-administration is achieved by injecting both peptides sequentially (or simultaneously at different injection sites), not by pre-mixing them in solution. Combining peptides in one vial risks cross-contamination, pH destabilization, and accelerated enzymatic breakdown that undermines the precise pharmacokinetic profiles these compounds are designed to deliver.